Mankind Pharma Share Price Target 2026: Analyst Forecast, Bull & Bear Case

Wed Apr 15 2026

Mankind Pharma (NSE: MANKIND) trades at Rs 1,850 as of April 2026 — against a 52-week high of Rs 2,800 and a 52-week low of Rs 1,650. The analyst consensus 12-month Mankind Pharma share price target is Rs 2,200–2,500, implying 19–35% upside. This article covers the key catalysts, risks, financial positioning, and a structured bull/bear case share price target for 2026 and beyond.

Get free SEBI-registered analyst research on Mankind Pharma on Univest.

Table of Contents

Mankind Pharma Share Price — Snapshot

Parameter	Value
CMP (April 2026)	Rs 1,850
52-Week High	Rs 2,800
52-Week Low	Rs 1,650
Market Cap	Rs 74,000 Cr
Trailing P/E	42x
NSE Ticker	MANKIND
Sector	Pharma / Consumer Health / OTC
12M Analyst Target	Rs 2,200–2,500
Bull Case	Rs 3,000
Bear Case	Rs 1,400
Upside (12M)	19–35%

Track Mankind Pharma live on the Univest Screener — fundamentals, FII/DII flows, analyst ratings.

About Mankind Pharma

Click Here — Get Free Investment Predictions on Univest.

Mankind Pharma is India’s fourth-largest pharma company by volume — and the most successful brand-builder in Indian OTC health. Prega News (pregnancy test), Gas-O-Fast, Unwanted-72, and AcneStar are dominant brands in their categories.

Key Growth Catalysts — Mankind Pharma Share Price Target

Tap to Access Best Research Pieces on Univest.

1. BSV Group Acquisition Synergies

BSV Group Acquisition Synergies — Women’s Health and Critical Care

2. Consumer OTC Brand Portfolio

Consumer OTC Brand Portfolio — Prega News 72% Market Share

3. India Branded Generic Volume Growth

India Branded Generic Volume Growth — Field Force Expansion

Key Risks to Watch

Risk 1: Integration of Rs 13,600 Cr BSV acquisition above market expectations

Integration of Rs 13,600 Cr BSV acquisition above market expectations

Risk 2: Promoter sell-down creating supply overhang perception

Promoter sell-down creating supply overhang perception

Mankind Pharma Share Price Target 2026

Subscribe to Univest Pro for premium analyst research on Mankind Pharma.

Short-Term Target (3–6 Months)

In the near term, Mankind Pharma is expected to trade in the Rs 1,650–Rs 2 range pending Q4 FY26 results and FY27 guidance clarity. The 52-week low of Rs 1,650 is the primary downside reference for position management.

12-Month Analyst Consensus Target

The analyst consensus 12-month Mankind Pharma share price target is Rs 2,200–2,500 — implying 19–35% upside from Rs 1,850. This consensus assumes the primary catalysts materialise and macro conditions stabilise. These are analyst projections, not guaranteed returns. Check live targets on the Univest Screener.

Long-Term Target (FY27–FY28)

The Mankind Pharma long-term target is Rs 3,000 in the bull case for FY27–28 — achievable if earnings delivery is consistent and catalysts accelerate. The bear case of Rs 1,400 represents the risk scenario if primary headwinds persist.

Scenario	Target Price	Key Assumption
Bear	Rs 1,400	Headwinds persist; earnings miss; macro adverse
Base (12M)	Rs 2,200–2,500	Catalysts deliver; earnings in line; macro stabilises
Bull	Rs 3,000	Catalysts accelerate; beat; sector re-rates

Download the Univest iOS App or Univest Android App for live Mankind Pharma price and SEBI-registered analyst alerts.

Conclusion

Mankind Pharma at Rs 1,850 offers risk-reward of 19–35% to the 12-month analyst consensus of Rs 2,200–2,500. The bull case of Rs 3,000 is achievable on full catalyst delivery; the bear case Rs 1,400 is the downside reference. Track Q4 FY26 results and FY27 management guidance as the primary near-term catalysts for validating the Mankind Pharma share price target thesis.

For more stock research, visit Univest Blogs.

Disclaimer: This article is for informational and educational purposes only and does not constitute investment advice. All analyst targets are estimates based on publicly available data as of April 2026. Investments in securities are subject to market risk. Please consult a SEBI-registered financial advisor before making any investment decisions.

Frequently Asked Questions

Q: What is Mankind Pharma share price target for 2026?

The 12-month analyst consensus Mankind Pharma share price target is Rs 2,200–2,500, implying 19–35% upside from Rs 1,850. Bull case is Rs 3,000; bear case is Rs 1,400. These are analyst projections, not guaranteed returns.

Q: What is Mankind Pharma’s current share price?

Mankind Pharma (NSE: MANKIND) trades at Rs 1,850 as of April 2026. 52-week high is Rs 2,800; 52-week low is Rs 1,650. Market cap is Rs 74,000 Cr.

Q: Is Mankind Pharma a good buy at current levels?

This article does not constitute investment advice. Mankind Pharma at Rs 1,850 has an analyst consensus target of Rs 2,200–2,500 implying 19–35% upside. Review catalysts and risks above and consult a SEBI-registered financial advisor before investing.

Q: What are the key risks for Mankind Pharma?

Primary risks: Integration of Rs 13,600 Cr BSV acquisition above market expectations. Additionally: Promoter sell-down creating supply overhang perception. Review the full risk analysis section for details.

Q: What is Mankind Pharma’s market cap and P/E?

Mankind Pharma has market cap of Rs 74,000 Cr and trailing P/E of 42x at Rs 1,850. 52-week range is Rs 1,650 to Rs 2,800.

Q: What are Mankind Pharma’s growth catalysts?

Three key catalysts: BSV Group Acquisition Synergies, Consumer OTC Brand Portfolio, and India Branded Generic Volume Growth.

Q: What is Mankind Pharma’s long-term target?

The Mankind Pharma long-term share price target for FY27–28 is Rs 3,000 in the bull case — assuming consistent earnings delivery and full catalyst materialisation.

Q: Where can I track Mankind Pharma live?

Track Mankind Pharma (NSE: MANKIND) live on the Univest Screener at univest.in/screeners. Download the Univest App for real-time alerts and SEBI-registered research.